The Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance.
| Autor: | Qunaj L; Department of Medicine, Columbia University, New York, New York., Lentzsch S; Department of Medicine, Columbia University, New York, New York.; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York., Neugut AI; Department of Medicine, Columbia University, New York, New York.; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2024 Dec 02; Vol. 33 (12), pp. 1547-1549. |
| DOI: | 10.1158/1055-9965.EPI-24-1405 |
| Abstrakt: | The identification of premalignant lesions in solid tumors such as colorectal and cervical cancer has led to the development of highly effective population-wide screening programs for these malignancies. Although precursor clinical states are not well-established for most hematologic malignancies, multiple myeloma is a notable exception. Virtually all patients with multiple myeloma first develop monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic but easily detectable condition. However, broad screening for MGUS has not been adopted primarily because there is no proven intervention to delay or prevent the progression of MGUS to multiple myeloma. Furthermore, the incidence of MGUS is poorly understood; a better understanding of its epidemiology will be critical in designing appropriate screening guidelines once an effective treatment has been developed. In the current issue of Cancer Epidemiology, Biomarkers & Prevention, Ji and colleagues provide important epidemiologic insights on MGUS, including a critical discussion on how its incidence and preclinical duration vary by age and race, acknowledging that both MGUS and multiple myeloma are more common in Black than White populations. See related article by Ji et al., p. 1690. (©2024 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|